(Total Views: 392)
Posted On: 07/20/2021 4:01:08 AM
Post# of 36564
"NGIO is currently conducting a phase II clinical trial of its leading immunotherapeutic cancer vaccine AE37 in combination with pembrolizumab (Keytruda® from Merck) for the treatment of triple negative breast cancer." 12/2020
Will the study still be carried out with Merck?
To be honest, I do not understand why Merck did not offer its support in vaccine development or why a collaboration is taking place. They actually know each other, but apparently they couldn't or didn't want to get Merck on board (for whatever reason) or Merck has gained a different picture of Generex in recent years and thus drew its conclusions from it.
Will the study still be carried out with Merck?
To be honest, I do not understand why Merck did not offer its support in vaccine development or why a collaboration is taking place. They actually know each other, but apparently they couldn't or didn't want to get Merck on board (for whatever reason) or Merck has gained a different picture of Generex in recent years and thus drew its conclusions from it.
(0)
(0)
